secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cryoport, Inc. (CYRX)
CIK:        0001124524
Form:       8-K
Filed at:   2023-05-04T23:59:59+00:00
Accession:  0001104659-23-056041
Event type: earnings
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Record Q1 revenue of $62.8M, up 20% YoY; net loss narrows to $0.16/share
------------------------------------------------------------------------

- Revenue $62.8M, +20% YoY (+23% constant currency); Biopharma/Pharma +19%, Animal Health +30%, Reproductive Medicine +13%.
- Net loss attributable to common stockholders $7.6M ($0.16/share) vs $15.4M ($0.31) YoY; adjusted EBITDA $2.9M vs $2.0M.
- Commercial cell and gene therapy revenue +28% YoY; supports 652 clinical trials (82 Phase 3) and 10 commercial therapies.
- Cash and short-term investments $522.6M; FY 2023 revenue guidance reaffirmed at $270-290M.
- New partnerships with Syneos Health (jan 2023), Inception Fertility (Mar 2023), and Boston IVF (Apr 2023).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124524/000110465923056041/0001104659-23-056041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124524/000110465923056041/tm2314749d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-056041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer